Matthew Blake, DO
Internal Medicine · Cynthiana, KYNPI 1578191250
Payments from drug & device makers
Across 90 payments — averaging $37.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- AbbVie$310
- GSK$146
- Teva Pharmaceuticals USA, Inc.$124
- Novo Nordisk$96
- Otsuka America Pharmaceutical, Inc.$71
- plus $816 from 25 others
What the payments were for
- Travel & lodging$89226%
- Food & beverage$1,59047%
- Education$91527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $1,834 |
| AbbVie | 18 | $310 |
| GSK | 6 | $146 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Novo Nordisk | 6 | $96 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Bayer | 4 | $66 |
| Corcept Therapeutics | 3 | $64 |
| Supernus Pharmaceuticals, Inc. | 2 | $56 |
| Alkermes, Inc. | 3 | $56 |
| Insulet Corporation | 3 | $54 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Lundbeck LLC | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Amgen | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Pfizer | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Biomerieux Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
How this compares
$3,398 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 92 | $409,227 |
| Austedo XrDeutetrabenazine | 21 | $113,315 |
| JardianceEmpagliflozin | 106 | $45,024 |
| XareltoRivaroxaban | 156 | $43,922 |
| Abilify MaintenaAripiprazole | 14 | $34,360 |
| EliquisApixaban | 86 | $26,349 |
| MounjaroTirzepatide | 23 | $24,733 |
| VraylarCariprazine Hcl | 27 | $23,882 |
| TradjentaLinagliptin | 85 | $22,719 |
| OzempicSemaglutide | 21 | $19,433 |
| FarxigaDapagliflozin Propanediol | 23 | $17,005 |
| RexultiBrexpiprazole | 21 | $14,615 |
| TrulicityDulaglutide | 13 | $14,501 |
| EntrestoSacubitril/Valsartan | 37 | $13,810 |
| JanuviaSitagliptin Phosphate | 41 | $13,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $124 | $522,542113 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $19 | $76,613209 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $71 | $48,97535 claims |
| Lilly USA, LLCMounjaro, Trulicity | $44 | $39,23436 claims |
| AbbVieVraylar, Linzess | $310 | $34,53942 claims |
| PfizerEliquis | $28 | $26,34986 claims |
| AstraZenecaFarxiga, Brilinta | $14 | $23,35359 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $146 | $22,99060 claims |
| Novo NordiskOzempic | $96 | $19,43321 claims |
| NovartisEntresto | $45 | $13,81037 claims |
| MerckJanuvia | $16 | $13,24741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Cynthiana
- John PeppinCynthiana$108K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.